Polaris Group announced the change to the Chief Executive Officer. Name, title, and resume of the previous position holder: Chen, Hung-Wen, Chairman of the Board and Name, title, and resume of the new position holder: Steve J.P. Hsu, Chairman & President of Genovior Biotech Corporation. Date of occurrence of the change: December 21, 2023.

Effective date: December 21, 2023. The newly appointed CEO, Dr. Steve Hsu, holds a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT) and has over 30 years of professional experience in the pharmaceutical industry. He is among the outstanding experts in organic chemistry synthesis.

Notably, his expertise extends to peptide drugs with over thirty amino acids, achieving exceptionally high yields through synthesis or semi-synthesis approach. Under his leadership, Genovior Biotech has successfully developed the widely sought-after drug "Semaglutide" for diabetes and weight management.